



Trendlines to Seek Dual Primary Listing and Securities Offer on Tel Aviv Stock Exchange

Aims to Expand Institutional Shareholder Base

Misgav, Israel and Singapore, 5 April 2021 – The board of directors (the “**Board**”) of The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries, “**Trendlines**” or the “**Group**”), the Israel and Singapore-based investment company focused on its mission of “creating and developing companies to improve the human condition” and profiting through innovation-based medical and agrifood technology investments, wishes to announce that the Company is proposing to seek a dual primary listing of its ordinary shares (“**Shares**”) on the Tel-Aviv Stock Exchange (“**TASE**”) in Israel (the “**Proposed TASE Listing**”).

The Trendlines Group considers that the Proposed TASE Listing will be beneficial for the Company, and in the interests of the shareholders of the Company (the “**Shareholders**”), while maintaining the Catalist listing of the Company on the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), for the following reasons:

- (a) The Israeli capital market has become very attractive for technological companies with growing interest from institutional investors. In recent months, there have been more than 40 IPOs on the TASE and to the best of the Company’s knowledge, the TASE is expecting as many as 70 IPOs during the first six months of 2021, many of which are technology companies. To the best of the Company’s knowledge, none of the contemplated IPOs involve companies offering a similar diversified portfolio to that offered by the Company;
- (b) The stock markets in Singapore and Israel attract different investors. Listings on both the SGX-ST and TASE will provide the Company with access to two different equity markets and easier shareholder access; and
- (c) The Proposed TASE Listing will strengthen fund-raising opportunities for the Company, broaden its shareholder base, and provide the Company with an additional source of capital to support the growth of the Company.

The Company, being an Israeli incorporated company, is strategically well-poised for the Proposed TASE Listing to attract new business partners and strategic investors in Israel, as well as to recruit, motivate and retain key management personnel for the business of the Group. Subject to market conditions, Trendlines plans to raise new capital with a public offering of new securities (the “**Proposed Securities Offer**”) in conjunction with the Proposed TASE Listing, of which at least 70% is expected to be subscribed by institutional investors.

The Company has on 31 March 2021, submitted an application to the Israeli Securities Authority (“ISA”) to publish a prospectus on the TASE. The Company is also in the midst of consulting with the SGX-ST on the Proposed TASE Listing and the Proposed Securities Offer.

The Proposed TASE Listing and the Proposed Securities Offer that may be made in conjunction with the Proposed TASE Listing are subject to, amongst others, approval from the TASE and ISA for the listing of, and offering of the Proposed Securities Offer through a prospectus on the TASE and, as applicable or required, other legal and/or regulatory approvals including the approval of Shareholders and the SGX-ST.

Shareholders should also note that, the completion of the Proposed TASE Listing will further be subject to the then prevailing market conditions. Further, the Directors of the Company may, notwithstanding that all relevant legal and/or regulatory approvals have been obtained, decide not to proceed with the Proposed TASE Listing and Proposed Securities Offer, if after assessing various factors including the prevailing general economic and capital market conditions, deem that it is not in the best interests of the Company to proceed with the same.

Accordingly, the Board wishes to caution that there is no certainty or assurance of this announcement that the Proposed TASE Listing and the Proposed Securities Offer may materialise.

Commenting on the Proposed TASE Listing, Chair and CEO Steve Rhodes remarked, “As Singapore continues to deepen its efforts to strengthen its technology capabilities and investment in innovation, we believe that listings on the SGX-ST and the TASE are complementary to the Group’s long-term vision of creating and developing medical and agrifood technology companies to improve the human condition.”

Chair and CEO Todd Dollinger added, “Interest in Trendlines and our portfolio companies from the Israeli investment community, including institutional investors, is clear and growing. We expect that our planned listing and public offering on the TASE will diversify and expand our shareholder base to include greater institutional ownership and higher market engagement. As the Israeli investment community, especially institutional investors, are receptive to and familiar with Trendlines’ business model, we expect greater liquidity to our shares and substantially increase our cash flow to meet our business strategy. Trendlines remains committed to protecting the interests of our retail and minority investors.”

The Board wishes to advise Shareholders and potential investors to exercise caution when dealing or trading in the securities/shares of the Company, and to refrain from taking any action which may be prejudicial to their interests. In the event of any doubt, Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers. Information disclosed in this announcement is also subject to change. The Company will make further announcements on SGXNET as and when there are material developments on this matter.

About The Trendlines Group Ltd.

Trendlines is an investment company that invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares

are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Jennifer Tan, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore:

Romil Singh, Financial PR

romil@financialpr.com.sg

Jass Lim, Financial PR

jass@financialpr.com.sg

Shivam Saraf, Financial PR

shivam@financialpf.com.sg

Tel: +65.6438.2990